VAERS Explorer
Back to explore

Report #2896888

Received May 18, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
Recovered
Unknown
Vaccinated
Apr 1, 2025
Onset
Apr 1, 2025
Days to onset
0
Hospital days

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
HEPABHEP A + HEP B (TWINRIX)GLAXOSMITHKLINE BIOLOGICALS2
HEPABHEP A + HEP B (TWINRIX)GLAXOSMITHKLINE BIOLOGICALS3UNK

Symptoms (2)

Inappropriate schedule of product administrationIncomplete course of vaccination

Symptom narrative

Longer than recommended interval between dose 2 and 3/ wanted to know if it was possible to administer the third dose; Longer than recommended interval between dose 1 and 2; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received first dose on 01-JAN-2025). On 01-APR-2025, the patient received the 2nd dose of Twinrix. The patient did not receive the 3rd dose of Twinrix. On 01-APR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Longer than recommended interval between dose 1 and 2). The patient had incomplete course of vaccination (Verbatim: Longer than recommended interval between dose 2 and 3/ wanted to know if it was possible to administer the third dose). The outcome of the drug dose administration interval too long and incomplete course of vaccination were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-MAY-2026 A pharmacist reported that a patient who received their first dose of Twinrix in January 2025 and their second dose on April 2025 wanted to complete the series. They wanted to know if it was possible to administer the third dose or if they needed to restart the series. The health care professional did not wish to provide any information about the vaccine and only provided limited information about the patient, stating that their gender was male. The batch number was not provided upon follow- up with the reporter.